menu search

Day one announces new firefly-1 data for tovorafenib (day101) and initiation of rolling nda submission to fda for relapsed or progressive pediatric low-grade glioma

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to ...

June 4, 2023, 4:45 pm

Abbvie (abbv) gets fda nod for lymphoma drug epcoritamab

The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large ...

May 22, 2023, 1:35 pm

Gracell biotechnologies to present clinical data on bcma/cd19 dual-targeting fastcar-t gc012f in rrmm and b-nhl and donor-derived car-t gc007g in b-all at eha2023 congress

First disclosure of data from Phase 1 study of the donor-derived allogeneic CAR-T GC007g shows 100% overall response rate (ORR) and a favorable safety...

May 11, 2023, 5:28 pm

Gracell biotechnologies to present updated clinical data on bcma/cd19 dual-targeting fastcar-t gc012f at 2023 asco annual meeting

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China , April 26, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: G...

April 26, 2023, 10:15 am

Bristol myers' (bmy) breyanzi gets positive chmp opinion

Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed ...

April 3, 2023, 1:41 pm

Karyopharm therapeutics: expanding beyond the crowded multiple myeloma market

Shares are down 50% over the past year as fierce competition in the multiple myeloma space negatively impacts Xpovio's growth prospects. However, ther...

March 20, 2023, 4:43 am

Glycomimetics: stock price drop brings great speculative trade opportunity

Independent Data Monitoring Committee interim analysis concludes that the phase 3 study, using uproleselan in combination with chemotherapy for the tr...

March 8, 2023, 11:20 pm

Day one reports fourth quarter and full year 2022 financial results and corporate progress

First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with...

March 6, 2023, 9:30 pm

Caribou: potential to improve response duration with higher dose level

Proof of concept established from the phase 1 ANTLER study in using Dose level 1 of CB-010 for the treatment of patients with ...

January 24, 2023, 7:12 am


Search within

Pages Search Results: